Kodiak Sciences Q2 EPS Forecast Increased by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright upped their Q2 2026 EPS estimates for shares of Kodiak Sciences in a research note issued on Monday, May 11th. HC Wainwright analyst M. Caufield now expects that the company will earn ($0.95) per share for the quarter, up from their prior estimate of ($0.96). HC Wainwright has a “Buy” rating and a $58.00 price objective on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($4.04) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.48) EPS, FY2027 earnings at ($2.92) EPS, FY2028 earnings at ($1.74) EPS, FY2029 earnings at $0.39 EPS and FY2030 earnings at $3.20 EPS.

A number of other equities research analysts also recently commented on KOD. UBS Group increased their price objective on Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Chardan Capital upgraded Kodiak Sciences from a “neutral” rating to a “buy” rating and increased their price target for the company from $14.00 to $61.00 in a research report on Monday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $42.14.

Kodiak Sciences Stock Performance

Shares of NASDAQ:KOD opened at $39.49 on Wednesday. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of -9.47 and a beta of 2.32. Kodiak Sciences has a 1-year low of $2.81 and a 1-year high of $47.84. The company has a 50 day moving average price of $35.72 and a 200 day moving average price of $28.07.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.01).

Institutional Trading of Kodiak Sciences

Large investors have recently added to or reduced their stakes in the company. KBC Group NV purchased a new stake in shares of Kodiak Sciences in the first quarter valued at $39,000. Swiss National Bank purchased a new position in shares of Kodiak Sciences during the first quarter valued at $2,188,000. Bank of New York Mellon Corp lifted its stake in Kodiak Sciences by 8.4% in the 1st quarter. Bank of New York Mellon Corp now owns 111,341 shares of the company’s stock worth $4,244,000 after acquiring an additional 8,628 shares in the last quarter. Westfuller Advisors LLC acquired a new stake in Kodiak Sciences during the 1st quarter worth about $26,000. Finally, V Square Quantitative Management LLC purchased a new position in Kodiak Sciences during the 1st quarter valued at about $26,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical?stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.